Ocugen, Inc. · NASDAQ:OCGN
Ocugen — Q2 2026 Earnings Presentation
11 slides from Ocugen's earnings presentation, Aug 6, 2026
Slide 1: Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies to Market
Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally
Slide 2: Pipeline: A quarter of execution across three programs
2 Pipeline A quarter of execution across three programs Ocugen – Second Quarter Business Update OCU410ST Stargardt Disease 100K U.S.+EU patients · No approved therapy ODD · RPDD · OMPD · ATMP Current Stage Phase 2/3 GARDian3 — Enrollment complete Ph1 Ph2 Ph3 BLA Approved Next Catalysts Interim outco
Slide 3: Current GA therapy targets the lesion; none target the vision
3 Current GA therapy targets the lesion; none target the vision — OCU410 was designed to do both 31% Lesion growth reduction vs. control (p<0.05) OCU410 Phase 2 ARMADA (12 months) Pivotal P3 population: (lesion size ≥2.5 mm2 and ≤17.5 mm2 ) 27% EZ preservation (correlates to visual function) Pivotal
Slide 4: OCU410 Global Phase 3 (ArMaDa 3) Trial Design for GA
Proposed Endpoints Primary • Rate of change (slope) of square root-transformed GA lesion area (√mm²/year) from baseline to Month 12, treated eyes vs control eyes as assessed by FAF Secondary • Proportion of subjects with LLVA ≥15 Letter Loss from Baseline to M12 as assessed by ETDRS visual charts at
Slide 5: First-in-Class Gene Therapy for Stargardt Disease
5 First-in-Class Gene Therapy for Stargardt Disease OCU410ST · Stargardt Disease 100K U.S. + EU patients No approved therapy globally Q3 2026 GARDian3 enrollment interim outcome Q2 2027 topline data expected EMA accepted single U.S. trial for MAA Stargardt is the most common inherited macular dystro
Slide 6: The largest orphan gene therapy trial ever run, targeting approval across all RP mutations
6 The largest orphan gene therapy trial ever run, targeting approval across all RP mutations OCU400 · Retinitis Pigmentosa 140 patients enrolled in Phase 3 liMeliGhT trial (largest orphan gene therapy Ph3) 100+ RP-causing genes addressed by a single subretinal injection Q1 2027 topline data expected
Slide 7: Three indications. 3+ million patients. Multibillion market.
7 Three indications. 3+ million patients. Multibillion market. Market Opportunity OCU410 — Geographic Atrophy 2–3M patients · U.S. + EU 2.5M+ untreated today $300-600k pricing assumption (market potential)1 Current treatment landscape unable to support visual gain OCU410ST — Stargardt Disease 100K p
Slide 8: OCU400 US Commercial Roadmap
OCU400 US Commercial Roadmap Payer engagement and CMS Center of Excellence Patient Registry Distribution Sales & Marketing • Increased engagement • Setup 25+ COEs • Enhance disease awareness • Frictionless supply • 1Q2026 TLR inflection point Commercial
Slide 9: Anticipated Milestones – Three BLAs by 2028
9 Milestones Anticipated Milestones – Three BLAs by 2028 Retinitis Pigmentosa Stargardt Disease Geographic Atrophy OCU400 OCU410ST OCU410 Interim outcome analysis1 Phase 3 topline data Initiate Phase 3 2026 2027 1Q 2Q 3Q 4Q Phase 3 topline data BLA Submission Approval/ Launch Approval/ Launch BLA Su
Slide 10: Financial Update: Three months ended June 30, 2026
Financial Update Statement of Operations Three months ended June 30, 2026 2025 Research and development expense $10.7 $8.4 General and administrative expense $7.2 $6.8 Interest (expense) income, net $(4.1) $(1.1) Other (expense) income, net $(4.4) $0.1 Net loss $(24.9) $(14.7) Balance Sheet Data Jun
Slide 11: Financial Update: Six months ended June 30, 2026
Financial Update Statement of Operations Six months ended June 30, 2026 2025 Research and development expense $21.9 $17.9 General and administrative expense $15.4 $13.2 Interest (expense) income, net $(5.3) $(2.0) Other (expense) income, net $(4.5) $0.2 Net loss $(44.1) $(30.1) Balance Sheet Data Ju